cancer gene therapy one t cell kills multiple tumor cells david l. liu, md, phd instructor in...
TRANSCRIPT
Cancer Gene TherapyOne T Cell Kills Multiple Tumor Cells
David L. Liu, MD, PhD
Instructor in Medicine, Assistant in Biology
Harvard Cancer Gene Therapy Center
BIDMC and Harvard Medical School
Background
Landmark of Adoptive Immunotherapy 1977, Rosenberg SA, et al. Passive Immunotherapy of cancer in animals and man 1985 Rosenberg-Lotz, LAK cells 1987 Spiess-Rosenberg, TILs 1987 Yamada, Human IL2 gene in murine T cells 1987 Kuwana, first reported IgTCR chimeric receptor 1995 Treisman-Hwu, IL2 transduced lymphocytes 2001 Maher-Sadelain, chimeric TCR/CD28 receptor 2002 R. Junghans, IgCD28TCR (Tandem) T cells 2003 Liu, IgTCR-GM-CSF transduced T cells
Classic Concept-1
Tumors are killed by LAK cells or TILs or IgTCR or Tandem-transduced T cells that is resulted from proliferation of injected T cells in tumor tissue.
Dr. Rosenberg wrote: LAK cells or TILs traffic to and accumulate in tumor deposits. This finding led to attempts to genetically alter TILs to increase their anti-tumor activity at the tumor site.
Classic Concept-2
In the past, Dr. Richard Junghans also wrote in application of research proposal: … He has freshed his concept because several new findings have been observed in BDL
Dr. James Mier also said Proliferation of injected T cells in tumor tissue is the mechanism killing tumor, everyone says so.
In 2003, an Israel research group still reported “proliferation of intratumorally injected IgTCR-TD T cells in tumor (Cancer Res), this is absolutely untrue.
Classic Concept-3
In the textbook of Cellular and Molecular Immunology, Dr. Abul Abbas writes:
1. CTL killing is antigen specific. 2. CTL killing requires cell contact. 3. CTLs themselves are not injured during lysis of target cells. 4. Suppose each individual CTL is capable of sequentially
killing multiple target cells, but so far no direct proof has been demonstrated.
Classic Concept-4
Dr. James Allison presented and demonstrated the modality how antigen presenting cells deliver a signal to T cells or to tumor cells. He was asked to answer how much long is needed for this process?
He didn’t have definite data, but we do have!
Classic Concept-5
Generally, it is easy to follow the hypothesis, assumption and theory that suggested by a great professor or big head.
Universally, it is hard to accept a new finding that conflicts with the traditional concept.
Hypothesis-1
Over the past 7 years, we examined >2000 tumor tissue slides in mice immunized with hybrid tumor vaccines, <5% of samples showed infiltration of T cells in tumor tissue.
During the past 14 months, we examined >100 tumor slides in nude mice treated with IgTCR or Tandem-TD T cells, no proliferation of IgTCR or Tandem-TD T cells was seen in tumor tissue.
Hypothesis-2
A tumor at size of 6x6mm in diameters (approximately 500x106 tumor cells) that could be cured with 50x106 transduced T cells in our in vivo therapy, how does one transduced T cell kill 5 to 10 tumor cells?
Hypothesis-3
If one T cell can really kill 5 to 10 tumor cells, what modality of killing process is it? Crazed T cells?
The killing process needs direct contact of TD-T cells and tumor cells, what contact modality is it? Leech Mouth-Like T Cells?
What morphology changes in T cells and tumor cells will happen when kiss-death of TD-T cells and tumor cells is initiated? Both cell types?
Materials and Methods Human PBLs from blood donor Transduced with IgTCR or IgTCR-CD28 viral sup. High percentage of transduced T cells (35-76%) 50x106 CFSE labeled and WI2 stained T cells I.v. Ex vivo killing tests: 5, 10, 15, 30, 60, 90, 120 min. In vivo proliferation in regressing tumor tissue Computed digital light microscope Invital fluoresence microscopy Confocal microscopy Flow cytometry
Stains-Double Labeling Of Cells
Labeling transduced T cells: CFSE, purified WI2 + GAM Rhodamine
Labeling ECA-expressing tumor cells Purified MN14 ab + GAM Rhodamine or PE
Anti-human CD3, CD8 T cell Immunochemical staining
IgTCR – chimeric immunoglobulin – T cell receptor
Ig CEA TCRModified
T Cell
Advantage: Conferring the specificity of antibody to TCR and bypassing the MHC-TCR pathway for T cell cytotoxicity
It is a prerequisite for a successful adoptive immunotherapy to have a large amount of T cells (1011).
Tumor Cell
CEA-Ig Fc Chimeric Molecule
Hypothesis: Utility of CEA-Ig Fc
• Detection of the expression of anti-CEA IgTCR molecule on themodified T cells
• Activation of the IgTCR modified T cells in vitro/in vivo
Fc CEA TCRModified
T Cell Ig
Cloning of anti-GD3 IgTCR, 2nd generation
CD28LTR gag scFV (anti-CEA)
LTRCD3zCD8h
Nco I Blp 12nd generation
Anti-CEAIgCD28Zeta
LTR gag scFV (anti-GD3)
LTRCD3zCD8h
Nco I Blp 11st generation
Anti-GD3IgTCR
Structure of the CEA-Ig Chimera Molecule
Constructs of IgTCR, Ig28TCR
Transgene
Transfection
Protein
Viral particle
Genome
Genome
Packaging cell line
Target cells
Integration
polgag
envpolgag
env
Viral RNA
DNA
Production of Retrovirus Particles
Producer cell line
Subpopulation of T cells during transfectionBC40, day 0 PBL
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
BC40, day 7 after transfection
0.0010.0020.0030.0040.0050.0060.0070.0080.0090.00
100.00
unstimulated OKT3 OKT3+CD28 PHA
CD4
CD25
CD16
CD3
CD8
CD28
CD56
CD14
CD64
* o
* *
o
oCD4/CD8 ratio: on day 7OKT3 2.08OKT3+CD28 2.08PHA 1.51
BC40, day 3 after activation
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
unstimulated OKT3 OKT3+CD28 PHA
CD4
CD25
CD16
CD3
CD8
CD28
CD56
CD14
CD64
*
* *
o o
o
Positively Transduced IgTCR or IgTCR-CD28 T Cells
76% positively transduced IgTCR T Cells
EXPERIMENTAL GROUPS
FIRST COURSE OF KILLING TESTT cells:Tumor cells = 3:1
Jurkat-ATCC (30x106) + MIP-CEA (10x106) Jurkat-IgTCR (30x106) + MIP-CEA (10x106) Jurkat-Tandem (30x106) + MIP-CEA (10x106)
Activated T cells (30x106) + MIP-CEA (10x106) IgTCR-TD T cells (30x106) + MIP-CEA (10x106) Tandem-TD T cells (30x106) + MIP-CEA (10x106)
FIRST COURSE OF KILLING TEST [2, 3, 4 and 5 days-AICD]
T Cells : Tumor Cells at 3:1 T Cells : Tumor Cells at 3:1
J-ATCC J-IgTCR J-Tandem Act. T IgTCR Tandem
No killing No killing No killing No Killing 40% 50%
No killing No killing No killing No Killing 60% 75%
No killing No killing No killing No Killing >90% 100%
No killing No killing No killing AICD AICD AICD
RE-ACTIVATION OR RE-KILLING: GROUPING
T cells:Tumor cells = 1:1
Activated T cells (30x106) + MIP-CEA (10x106)
IgTCR-TD T cells (30x106) + MIP-CEA (10x106)
Tandem-TD T cells (30x106) + MIP-CEA (10x106)
T cells:Tumor cells = 3:1 Activated T cells (30x106) + MIP-CEA (10x106)
IgTCR-TD T cells (30x106) + MIP-CEA (10x106)
Tandem-TD T cells (30x106) + MIP-CEA (10x106)
RE-KILLING TEST (Day 2, 3 (AICD), 8)
T Cells : Tumor Cells at 1:1 T Cells : Tumor Cells at 3:1
Act. T IgTCR Tandem Act. T IgTCR Tandem
No killing 5% 5% No Killing 40% 50%
No killing 20% 25% No Killing 60% 80%
No killing AICD AICD No Killing AICD AICD
No killing 40% 10% 60% 25% 10%
re-growing re-growing re-growing
CEA- Control CEA+ Regressed
Human CEA+ Cancer Regressed after Gene Therapy
Human CEA+ Cancer Regressed after Gene Therapy
One Gene Transfected T Cell Kills Multiple Tumor Cells
Apoptosis in Tumor Cell
Leech Mouth-Like T Cells
Leech Mouth-Like T Cells
Leech Mouth-Like T Cells
Injected TD-T cells in Spleen (2hs)
Homing or Proliferation of TD-T Cells in Spleen
(Enlarged from the last slid)
Necessary Time For Change In T Cell Morphology
5 min no change in morphology15 min no change in morphology30 min 5-10% T cells had change in morphology45 min 15% T cells had change in morphology60 min 20% T cells had change in morphology2hs 30% T cells had change in morphology
Blue Color Shows Perforin Produced by Gene Transfected T Cells
Blue Color Shows Perforins Produced by Gene Transfected T cells
Centralized Killing Modality of T Cells
Conclusion1. IgTCR or IgTCR-CD28 gene transfected T cells induced massive
necrosis of CEA-expressing human colon cancer from day 1 to day 3 after treatment.
2. A new finding, leech mouth-like T cells are plunged onto surface of CEA-expressing tumor cells, is for the first time described.
3. Direct evidences of one T cell kills >5 tumor cells in vivo have been confirmed by 3 types of specific staining, HE staining, anti-hCD3 immunochemical staining and CFSE labeling-TD T cells.
4. The modality of centralized T cells killing tumor cells in vivo has been consistently observed.
5. Injected TD-T cells in vivo have 3 fates: reactivation and killing tumor cells inside tumor; proliferation in spleen and re-circulation into tumor; and become apoptotic or activation induced cells death.
6. No evidence of proliferation of T cells in tumor was seen.